Glenohumeral OsteoArthritis Therapy Trial

Part of paid clinical trials in Buffalo, New York.

Sponsor
State University of New York at Buffalo
Study ID
NCT07744542
Status
Enrolling By Invitation

Conditions

  • Glenohumeral Arthritis
  • Shoulder Arthritis Osteoarthritis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Physical therapy — BEHAVIORAL
    12 weeks of designated physical therapy focused on improving shoulder strength and range of motion
  • Home physical therapy — BEHAVIORAL
    12 weeks of home therapy program focused on improving shoulder strength and range of motion

Study Details

Arthritis of the shoulder glenohumeral joint is a growing problem in an aging population. Treatment options for glenohumeral arthritis can be grouped into three main categories: 1) shoulder replacement surgery, 2) injections (corticosteroid, hyaluronic acid and PRP) and physical therapy (PT). Surgery comes with risks and the potential for implant failure or revision over time. Therefore, it is typical for doctors to prescribe injections and/or PT before discussing surgery. Sometimes, insurance companies will require PT before considering a shoulder operation. It is unknown if PT is effective for improving function or pain with patients with glenohumeral arthritis. The aim of this study is to compare pain and functional outcomes after undergoing a 12 week PT program, at home PT exercises or delaying conservative treatment.

Key Dates

First listed
Aug 4, 2026
Start date
Jun 17, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
125 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Physical Therapy
    12 weeks of designated physical therapy focused on improving shoulder strength and range of motion
  • Experimental: Home Therapy
    12 weeks of home therapy program focused on improving shoulder strength and range of motion
  • No Intervention: Control Group
    Subjects continue with coping mechanisms for 12 week period, no intervention

Primary Outcome Measure

Visual analog scale (VAS) [ Time Frame: Time 0, 6 weeks, 12 weeks, 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
UBMD Orthopaedics & Sports MedicineBuffaloNew York14221-2108-

Find similar trials in Buffalo, NY

Related Studies